Tesla has been somewhat immune to the crisis with its shares jumping 3.2% to $587.02 at 10:11 EST on Thursday, following yesterday's upward trend. The Nasdaq Stock Market is sliding 0.05% to $12,349.40, following yesterday's downward trend, on what up to now seems, a somewhat rough trend exchanging session today.
Tesla's last close was $584.76, 3.54% below its 52-week high of $607.80.
News about Tesla today
Tesla gains after goldman seizes street-high target in upgrade. According to today's article on Bloomberg Quint, "Goldman Sachs is newly bullish on Tesla Inc., upgrading the electric-car manufacturer to a buy rating from neutral and raising its price target to $780, now the highest on Wall Street."
Tesla jumps after goldman sachs upgrades the automaker's stock and boosts its price target by 40%. According to today's article on Business Insider, "Shares in Tesla jumpeded on Thursday after Goldman Sachs upgraded its stock to "buy" from "neutral" and boosted its price target to $780, currently the highest on Wall Street."
An $11 billion tech-focused hedge fund scored a 52% gain by betting on Tesla and against scandal-ridden wirecard this year, a report said. According to today's article on Business Insider, "New York-based Coatue Management has been one of the best-performing big hedge funds in 2020, scoring a gain of 52% through November. "
Tesla bear Jim Chanos says he’d tell Elon Musk ‘job well done’. According to today's article on Bloomberg Quint, "Jim Chanos has been short Tesla Inc.'s stock for five long years. And although he's reduced the size of the trade, he's not done with it yet."
Tesla's Sales
Tesla's sales growth is 36.1% for the present quarter and 60% for the next. The company's growth estimates for the current quarter and the next is 112.2% and 265.2%, respectively.
Tesla's Revenue
Year-on-year quarterly revenue growth grew by 39.2%, now sitting on 28.18B for the twelve trailing months.
Tesla's Stock Top and Bottom Yearly Value
Tesla's stock is valued at $587.02 at 10:11 EST, under its 52-week high of $607.80 and way above its 52-week low of $65.45.
Tesla's Moving Average
Tesla's worth is way higher than its 50-day moving average of $453.29 and way above its 200-day moving average of $345.48.
Last two days news about Tesla
Tesla to enter S&P 500 at full weight in December. According to The Wall Street Journal on Tue Dec 1, "S&P Dow Jones Indices said it will add Tesla Inc.âs full weight to the S&P 500 all at once in December, shedding more light on a mammoth addition that has captivated investors across Wall Street."
S&P's decision to add Tesla in one shot demonstrates the power of passive investing. According to CNBC on Tue Dec 1, "Standard & Poor's action on Tesla showed the growing power of indexers and passive investing."
Musk urges Tesla staff to pinch pennies, buoy surging shares. According to Bloomberg Quint on Tue Dec 1, "Tesla Inc. Chief Executive Officer Elon Musk warned in an internal email his company's rallying shares could get crushed if investors start to worry about the electric-car manufacture."
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
